EGFR T790M位点突变型非小细胞肺癌耐药机制及耐药后的综合治疗
EGFR T790M Site-Mutated Non-Small Cell Lung Cancer Drug Resistance Mechanism and Comprehensive Treatment after Drug Resistance
摘要: 肺癌是目前发生率和死亡率最高的恶性肿瘤之一。非小细胞肺癌(non-small cell lung cancer, NSCLC)占肺癌发病总数的85%左右，其中约40%左右的患者存在表皮生长因子受体(epidermal growth factor receptor, EGFR)突变。表皮生长因子受体(epidermal growth factor receptor, EGFR)–酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKIs)是具有表皮生长因子受体(epidermal growth factor recep-tor, EGFR)基因敏感突变的晚期非小细胞肺癌患者的一线治疗药物，但大多数患者不可避免地会出现耐药问题。本文对EGFR T790M位点突变型非小细胞肺癌的耐药机制及耐药后治疗的研究进展进行综述。
Abstract: Lung cancer is one of the malignant tumors with the highest incidence and mortality at present. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, and about 40% of patients have epidermal growth factor receptor (EGFR) mutations. Epidermal growth factor recep-tor-tyrosine kinase inhibitors (EGFR-TKIs) are first-line therapy for patients with advanced non- small cell lung cancer (NSCLC) who have EGFR-sensitive mutations, but most patients inevitably develop resistance problems. In this review, we reviewed the research progress of drug resistance mechanism and post-drug resistance treatment of EGFR T790M mutant non-small cell lung cancer.
文章引用：武卉淇, 马金华. EGFR T790M位点突变型非小细胞肺癌耐药机制及耐药后的综合治疗[J]. 临床医学进展, 2022, 12(7): 6872-6881. https://doi.org/10.12677/ACM.2022.127991

参考文献

[1] Wu, Y.L., Zhong, W.Z., Li, L.Y., et al. (2007) Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology, 2, 430-439. [Google Scholar] [CrossRef] 
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30. [Google Scholar] [CrossRef] [PubMed]
[3] 何婧怡, 吴芳, 胡春宏. 第三代EGFR-TKIs治疗晚期非小细胞肺癌的耐药机制及应对策略研究进展[J]. 肿瘤防治研究, 2019, 46(10): 938-945.
[4] 中国临床肿瘤学会肿瘤生物标志物专家委员会, 《中国非小细胞肺癌患者EGFRT T790M基因突变检测专家共识》制定专家组. 中国非小细胞肺癌患者EGFR T790M基因突变检测专家共识[J]. 中华医学杂志, 2018, 98(32): 2544-2551.
[5] Nagano, T., Tachihara, M. and Nishimura, Y. (2018) Mechanism of Resistance to Epidermal Growth Factor Receptor- Tyrosine Ki-nase Inhibitors and a Potential Treatment Strategy. Cells, 7, Article No. 212. [Google Scholar] [CrossRef] [PubMed]
[6] Lynch, T.J., Bell, D.W., Sordella, R., et al. (2020) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medicine, 350, 2129- 2139. [Google Scholar] [CrossRef] 
[7] Mok, T.S., Wu, Y.L., Ahn, M.J., et al. (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine, 376, 629-640. [Google Scholar] [CrossRef] 
[8] Matikas, A., Mistri-otis, D., Georgoulias, V., et al. (2015) Current and Future Approaches in the Management of Non- Small-Cell Lung Cancer Patients with Resistance to EGFR TKIs. Clinical Lung Cancer, 16, 252-261. [Google Scholar] [CrossRef] [PubMed]
[9] 赵佳, 陈建业, 汤建才. 非小细胞肺癌吉非替尼耐药机制及治疗研究进展[J]. 中国现代应用药学, 2017, 34(6): 923-927.
[10] Kobayashi, S., Boggon, T.J., Dayaram, T., et al. (2005) EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medi-cine, 352, 786-792. [Google Scholar] [CrossRef] 
[11] Lin, L. (2010) Mechanisms of Drug Resistance to Gefifinib and Erlotinib. International Journal of Oncology, 37, 734-736.
[12] Park, K., Tan, E.H., O’Byrne, K., et al. (2016) Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial. The Lancet Oncology, 17, 577-589. [Google Scholar] [CrossRef] 
[13] 侯冉, 胡泊, 史健. EGFR T790M突变在非小细胞肺癌中的研究进展[J]. 肿瘤防治研究, 2020, 47(6): 471-476.
[14] Mukohara, T., Engelman, J.A., Hanna, N.H., et al. (2005) Differential Effects of Gefitinib and Cetuximab on Non- Small-Cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 97, 1185-1194.
[15] Okabe, T., Okamoto, I., Tsu-kioka, S., et al. (2009) Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines with MET Amplification. Clinical Cancer Research, 15, 907-913.
[16] Cho, B.C., Kim, H.J. and Sun, M.L. (2013). Abstract 5408: Enhancement of the Anti-Tumor Activity of Afatinib by Inhibition of Glycolysis in Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation. Cancer Re-search, 73, 5408.[CrossRef] 
[17] Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Jänne, P.A. and Oxnard, G.R. (2015) Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M. Nature Medicine, 21, 560-562. [Google Scholar] [CrossRef] [PubMed]
[18] Yu, H.A., Tian, S.K., Drilon, A.E., et al. (2015) Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M- Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncology, 1, 982-984. [Google Scholar] [CrossRef] [PubMed]
[19] Ercan, D., Choi, H.G., Yun, C.H., et al. (2015) EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhib-itors. Clinical Cancer Research, 21, 3913-3923. [Google Scholar] [CrossRef] 
[20] Niederst, M.J., Hu, H., Mulvey, H.E., et al. (2015) The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research, 21, 3924-3933. [Google Scholar] [CrossRef] 
[21] Mehlman, C., Cadranel, J., Rous-seau-Bussac, G., et al. (2019) Resistance Mechanisms to Osimertinib in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: A Multicentric Retrospective French Study. Lung Cancer, 137, 149-156. [Google Scholar] [CrossRef] [PubMed]
[22] Ortiz-Cuaran, S., Scheffler, M., Plenker, D., et al. (2016) Het-erogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Re-search, 22, 4837-4847. [Google Scholar] [CrossRef] 
[23] Xu, C., Wang, W., Zhu, Y., et al. (2019) Potential Re-sistance Mechanisms Using Next Generation Sequencing from Chinese EGFR T790M+ Non-Small Cell Lung Cancer Patients with Primary Resistance to Osimertinib: A Multicenter Study. Annals of Oncology, 30, II48. [Google Scholar] [CrossRef] 
[24] 刘超, 刘明辉, 刘红雨, 陈军. 奥希替尼在非小细胞肺癌中的耐药机制研究进展[J]. 中国医学前沿杂志(电子版), 2020, 12(7): 7-11.
[25] Planchard, D., Loriot, Y., André, F., et al. (2015) EGFR-Independent Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M-Positive NSCLC Patients. Annals of Oncology, 26, 2073-2078. [Google Scholar] [CrossRef] [PubMed]
[26] Alzahrani, A.S. (2019) PI3K/Akt/mTOR Inhibitors in Cancer: At the Bench and Bedside. Seminars in Cancer Biology, 59, 125-132. [Google Scholar] [CrossRef] [PubMed]
[27] Kim, T.M., Song, A., Kim, D.W., et al. (2015) Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. Journal of Thoracic Oncology, 10, 1736-1744. [Google Scholar] [CrossRef] 
[28] Barnes, T.A., O’Kane, G.M., Vincent, M.D., et al. (2017) Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 7, Article No. 113. [Google Scholar] [CrossRef] [PubMed]
[29] Le, X., Puri, S., Negrao, M.V., et al. (2018) Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy beyond Progres-sion in EGFR-Mutant NSCLC. Clinical Cancer Research, 24, 6195-6203. [Google Scholar] [CrossRef] 
[30] Oxnard, G.R., Hu, Y., Mileham, K.F., et al. (2018) As-sessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology, 4, 1527- 1534. [Google Scholar] [CrossRef] [PubMed]
[31] 裴清华, 孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 105-112.
[32] Lim, S.M., Kim, H.R., Cho, E.K., et al. (2016) Targeted Sequencing Identifies Genetic Alterations that Confer Primary Resistance to EGFR Tyrosine Kinase Inhibitor (Korean Lung Cancer Consortium). Oncotarget, 7, 36311-36320. [Google Scholar] [CrossRef] [PubMed]
[33] Ercan, D., Xu, C., Yanagita, M., et al. (2012) Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 2, 934-947. [Google Scholar] [CrossRef] 
[34] Minari, R., Bordi, P., Del Re, M., et al. (2018) Primary Re-sistance to Osimertinib Due to SCLC Transformation: Issue of T790M Determination on Liquid Re-Biopsy. Lung Can-cer, 115, 21-27. [Google Scholar] [CrossRef] [PubMed]
[35] Li, L., Wang, H., Li, C., et al. (2017) Transformation to Small-Cell Carcinoma as an Acquired Resistance Mechanism to AZD9291: A Case Report. Oncotarget, 8, 18609-18614. [Google Scholar] [CrossRef] [PubMed]
[36] Ham, J.S., Kim, S., Kim, H.K., et al. (2016) Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma during AZD9291 Treatment. Journal of Thorac-ic Oncology, 11, E1-E4. [Google Scholar] [CrossRef] [PubMed]
[37] Taniguchi, Y., Horiuchi, H., Morikawa, T., et al. (2018) Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. Case Reports in Oncology, 11, 323-329. [Google Scholar] [CrossRef] [PubMed]
[38] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. (2011) Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 3, 75ra26. [Google Scholar] [CrossRef] [PubMed]
[39] Lee, J.K., Lee, J., Kim, S., et al. (2017) Clonal History and Ge-netic Predictors of Transformation into Small-Cell Carcinomas from Lung Adenocarcinomas. Journal of Clinical Oncol-ogy, 35, 3065-3074. [Google Scholar] [CrossRef] 
[40] Niederst, M.J., Sequist, L.V., Poirier, J.T., et al. (2015) RB Loss in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to Small-Cell Lung Cancer. Nature Communications, 6, Article No. 6377. [Google Scholar] [CrossRef] [PubMed]
[41] Weng, C.H., Chen, L.Y., Lin, Y.C., et al. (2019) Epitheli-al-Mesenchymal Transition (EMT) beyond EGFR Mutations Per Se Is a Common Mechanism for Acquired Resistance to EGFR TKI. Oncogene, 38, 455-468. [Google Scholar] [CrossRef] [PubMed]
[42] Ichihara, E., Westover, D., Meador, C.B., et al. (2017) SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research, 77, 2990-3000. [Google Scholar] [CrossRef] 
[43] Yochum, Z.A., Cades, J., Wang, H., et al. (2019) Targeting the EMT Transcription Factor TWIST1 Overcomes Resistance to EGFR Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. Oncogene, 38, 656-670. [Google Scholar] [CrossRef] [PubMed]
[44] Wang, X., Zhou, L., Yin, J.C., et al. (2019) Lung Adenocarci-noma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Com-bination Therapy. Journal of Thoracic Oncology, 14, E85-E88. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, Z. and Wu, Y.L. (2019) Re-Emerging C797S in Trans and Rechallenge of Osimertinib with Erlotinib. Journal of Thoracic Oncology, 14, E81-E82. [Google Scholar] [CrossRef] [PubMed]
[46] Shi, P., Oh, Y.T., Zhang, G., et al. (2016) Met Gene Amplification and Protein Hyperactivation Is a Mechanism of Resistance to Both First and Third Generation EGFR Inhibitors in Lung Cancer Treatment. Cancer Letters, 380, 494-504. [Google Scholar] [CrossRef] [PubMed]
[47] Oxnard, G.R., Yang, J.C.H., Yu, H., et al. (2020) TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined with Selumetinib, Savolitinib, or Durvalumab in EGFR-Mutant Lung Cancer. Annals of Oncology, 31, 507-516. [Google Scholar] [CrossRef] [PubMed]
[48] La Monica, S., Cretella, D., Bonelli, M., et al. (2017) Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines. Journal of Experimental & Clinical Cancer Research, 36, 174. [Google Scholar] [CrossRef] [PubMed]
[49] Nakatani, K., Yamaoka, T., Ohba, M., et al. (2019) KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Har-boring Exon 19 Deletion/T790M in EGFR. Molecular Cancer Therapeutics, 18, 112-126. [Google Scholar] [CrossRef] 
[50] Yang, D., Dai, R., Zhang, Q., et al. (2018) Apatinib for Heavily Treated Patients with Non-Small Cell Lung Cancer: Report of a Case Series and Literature Review. Saudi Jour-nal of Biological Sciences, 25, 888-894. [Google Scholar] [CrossRef] [PubMed]
[51] Marcoux, N., Gettinger, S.N., O’Kane, G., et al. (2019) EGFR-Mutant Adenocarcinomas that Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 37, 278-285. [Google Scholar] [CrossRef] 
[52] Park, K., Haura, E.B., Leighl, N.B., et al. (2021) Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39, 3391-3402. [Google Scholar] [CrossRef] 
[53] Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J., Gukasyan, J., Williams, T., Sauer, L., Wells, C., Hardy, A., Linares, P., Lim, C., Ma, L., Adame, C. and Ga-ron, E.B. (2018) A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Pa-tients with Advanced NSCLC. Journal of Thoracic Oncology, 13, 1138-1145. [Google Scholar] [CrossRef] [PubMed]
[54] Piotrowska, Z., Niederst, M.J., Karlovich, C.A., et al. (2015) Het-erogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 5, 713-722. [Google Scholar] [CrossRef] 

为你推荐